Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | EVP, Chief Medical Officer | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 · Expires 2036-09-07 | Direct | 950,000 |
Reported balance
After 2026-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-08 · Grant · Acquired 950,000 · Balance 950,000 F1: This option was granted on September 8, 2026 and is scheduled to vest over four years, with 25% of the shares to vest on October 15, 2027 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 15, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on September 8, 2026 and is scheduled to vest over four years, with 25% of the shares to vest on October 15, 2027 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 15, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 9, 2026 20:58 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 950,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0002149618-26-000006 · wk-form4_1788987497.xml · derivative · entry 1 Ory Daniel Scott · CIK 0002149618 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 950,000 Underlying: Common Stock · 950,000 shares Expires 2036-09-07 F1 · derivative.exercise_date: This option was granted on September 8, 2026 and is scheduled to vest over four years, with 25% of the shares to vest on October 15, 2027 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 15, 2030. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.